Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season.
van Hage-Hamsten M, Kronqvist M, Zetterström O, Johansson E, Niederberger V, Vrtala S, Grönlund H, Grönneberg R, Valenta R. van Hage-Hamsten M, et al. Among authors: gronneberg r. J Allergy Clin Immunol. 1999 Nov;104(5):969-77. doi: 10.1016/s0091-6749(99)70077-1. J Allergy Clin Immunol. 1999. PMID: 10550741
Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
Gafvelin G, Thunberg S, Kronqvist M, Grönlund H, Grönneberg R, Troye-Blomberg M, Akdis M, Fiebig H, Purohit A, Horak F, Reisinger J, Niederberger V, Akdis CA, Cromwell O, Pauli G, Valenta R, van Hage M. Gafvelin G, et al. Among authors: gronneberg r. Int Arch Allergy Immunol. 2005 Sep;138(1):59-66. doi: 10.1159/000087358. Epub 2005 Aug 11. Int Arch Allergy Immunol. 2005. PMID: 16103688 Clinical Trial.
Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients.
Nopp A, Halldén G, Lundahl J, Johansson E, Vrtala S, Valenta R, Grönneberg R, Van Hage-Hamsten M. Nopp A, et al. Among authors: gronneberg r. J Allergy Clin Immunol. 2000 Jul;106(1 Pt 1):101-9. doi: 10.1067/mai.2000.106924. J Allergy Clin Immunol. 2000. PMID: 10887312
Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis.
van Hage-Hamsten M, Johansson E, Roquet A, Peterson C, Andersson M, Greiff L, Vrtala S, Valenta R, Grönneberg R. van Hage-Hamsten M, et al. Among authors: gronneberg r. Clin Exp Allergy. 2002 Oct;32(10):1448-53. doi: 10.1046/j.1365-2745.2002.01495.x. Clin Exp Allergy. 2002. PMID: 12372124 Clinical Trial.
Higher immunoglobulin E antibody levels to recombinant Fel d 1 in cat-allergic children with asthma compared with rhinoconjunctivitis.
Grönlund H, Adédoyin J, Reininger R, Varga EM, Zach M, Fredriksson M, Kronqvist M, Szepfalusi Z, Spitzauer S, Grönneberg R, Valenta R, Hedlin G, van Hage M. Grönlund H, et al. Among authors: gronneberg r. Clin Exp Allergy. 2008 Aug;38(8):1275-81. doi: 10.1111/j.1365-2222.2008.03003.x. Epub 2008 May 12. Clin Exp Allergy. 2008. PMID: 18477016
64 results